9 results
To compare exposure to ciprofloxacin between patients with impaired renal function (eGFR < 30 ml/min/1.73m2) admitted to a general ward in the AMC or OLVG location Oost receiving the revised reduced doses (test), patients with impaired renal…
The objective of this prospective, randomized study is to investigate the efficacy and safety of HSCT compared to the comparator group (alemtuzumab, cladribine or ocrelizumab) in patients with aggressive relapsing remitting MS. In Norway, the…
The objective of this trial is to establish if adding antibiotic treatment to surgical drainage of perianalabscess results in less perianal fistulas.
With this study we aim to prove that personalized B cell tailored ocrelizumab treatment is non-inferior in the suppression of MS disease activity (clinically and radiologically) compared to the standard (fixed 24 week interval) treatment.
This Extension study will evaluate the effectiveness and safety of ocrelizumab in MS patients who were previously enrolled in a Roche sponsored ocrelizumab phase IIIb/IV parent trial.
This study will evaluate the effectiveness and safety of ocrelizumab in PMS patients.
The purpose of this first-in-human study is to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses (MADs) of DYNE-101 administered intravenously (IV) to participants with DM1.…
Main objective:English To evaluate the longer-term safety of ocrelizumab in participants diagnosed with MS who were previously enrolled in Roche-sponsored\ Phase III pivotal studiesSecondary objectives:English To evaluate the longer-term efficacy of…
The primary objective is to investigate if a very short-course of antibiotics for cholangitis after adequate drainage is non-inferior with respect to clinical cure in comparison with a standard course of antibiotics.